


Build your own complimentary poster for the office!



Supplement your Course Learning. It's fast and easy.



We'll ship it to you directly free of charge




NONTUBERCULOUS MYCOBACTERIAL LUNG DISEASE (NTM-LD)

*for Pulmonary and Infectious
Disease Professionals:*

KEY PERSPECTIVES ON EXPERT
DIAGNOSIS AND MANAGEMENT

Please visit ntm-ld.posterprogram.com



NONTUBERCULOUS MYCOBACTERIAL LUNG DISEASE (NTM-LD)

*for Pulmonary and Infectious
Disease Professionals:*

**KEY PERSPECTIVES ON EXPERT
DIAGNOSIS AND MANAGEMENT**

ANIMATIONS

NTM - Epidemiology: <https://www.youtube.com/watch?v=47UO9BKLoPs>

NTM - Treatment: <https://www.youtube.com/watch?v=2sn3QyqkOmg>

*Use your devices' QR code scanner to view this
content in the **YOUTUBE APP!***



**Nontuberculous Mycobacterial Lung Disease (NTM-LD):
Nontuberculous Mycobacterial Lung Disease (NTM-LD) for Pulmonary and Infectious Disease
Professionals: Key Perspectives on Expert Diagnosis and Management**

Resource	Address
Adjemian J, Prevots DR, Gallagher J, Heap K, Gupta R, Griffith D. Lack of adherence to evidence-based treatment guidelines for nontuberculous mycobacterial lung disease. <i>Ann Am Thorac Soc.</i> 2014;11:9-16.	https://pubmed.ncbi.nlm.nih.gov/24236749/
Agheli A, Tehranirad M, Cofsky R. An unusual presentation of mycobacterium fortuitum: Massive isolated empyema in a patient with HIV infection. <i>MedGenMed.</i> 2006;8:90.	https://pubmed.ncbi.nlm.nih.gov/16926829/
Ahmed I, Tiberi S, Farooqi J, et al. Non-tuberculous mycobacterial infections—A neglected and emerging problem. <i>Int J Infect Dis.</i> 2020;92S:S46-S50.	https://pubmed.ncbi.nlm.nih.gov/32114200/
Ali J. A multidisciplinary approach to the management of nontuberculous mycobacterial lung disease: A clinical perspective. <i>Expert Rev Respir Med.</i> 2021;15:663-673.	https://pubmed.ncbi.nlm.nih.gov/33593217/
Boyle D Zembower TR, Qi C. Relapse versus reinfection of mycobacterium avium complex pulmonary disease. Patient characteristics and macrolide susceptibility. <i>Ann Am Thorac Soc.</i> 2016;13:1956-1961.	https://pubmed.ncbi.nlm.nih.gov/27599038/
Brode SK, Daley CL, Marras TK. The epidemiologic relationship between tuberculosis and non-tuberculous mycobacterial disease: A systematic review. <i>Int J Tuberc Lung Dis.</i> 2014;18:1370-1377.	https://pubmed.ncbi.nlm.nih.gov/25299873/
Calabrese C, Winthrop KL. Mycobacterial infections potentiated by biologics. <i>Infect Dis Clin North Am.</i> 2020;34:413-423.	https://pubmed.ncbi.nlm.nih.gov/32444014/
Centers for Disease Control and Prevention. Healthcare-associated infections. Nontuberculous mycobacteria. Last reviewed August 12, 2019.	www.cdc.gov/hai/organisms/ntm/clinicians.html Accessed 10/7/2021.
Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: An official ATS/ERS/ESCMID/IDSA clinical practice guideline. <i>Clin Infect Dis.</i> 2020;71:905-913.	https://pubmed.ncbi.nlm.nih.gov/32797222/
Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. <i>Eur Respir J.</i> 2020;56:2000535.	https://pubmed.ncbi.nlm.nih.gov/32636299/
Diel R, Nienhaus A, Ringshausen FC, et al. Microbiologic outcome of interventions against Mycobacterium avium	https://pubmed.ncbi.nlm.nih.gov/29410162/

<p>complex pulmonary disease: A systematic review. <i>Chest.</i> 2018;153:888-921.</p>	
<p>Finch S, van der Laan R, Crichton M, et al. M8 Non-tuberculous mycobacteria testing in bronchiectasis in the UK: Data from the EMBARC registry. <i>Thorax.</i> 2019;74(suppl 2):A238-A239.</p>	<p>https://thorax.bmj.com/content/74/Suppl_2/A238</p>
<p>Gido RDS, Wojciechowski AL, Bajwa RP. Pulmonary infection with <i>Mycobacterium szulgai</i>: A case report. <i>SAGE Open Med Case Rep.</i> 2019;7:1-4.</p>	<p>https://journals.sagepub.com/doi/pdf/10.1177/2050313X18823448</p>
<p>Griffith DE, Brown-Elliott BA, Benwill JL, Wallace RJ Jr. <i>Mycobacterium abscessus</i>. "Pleased to meet you, hope you guess my name...". <i>Ann Am Thorac Soc.</i> 2015;12:436-439.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/25643064/</p>
<p>Griffith DE, Eagle G, Thomson R, et al. Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by <i>Mycobacterium avium</i> complex (CONVERT). A prospective, open-label, randomized study. <i>Am J Respir Crit Care Med.</i> 2018;198:1559-1569.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/30216086/</p>
<p>Gutierrez C, Somoskovi A. Human Pathogenic Mycobacteria. Reference Module in: <i>Biomedical Sciences.</i> Elsevier 2014.</p>	<p>www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/mycobacterium-chelonae</p>
<p>Hong SJ, Kim TJ, Lee JH, Park JS. Nontuberculous mycobacterial pulmonary disease mimicking lung cancer: Clinicoradiologic features and diagnostic implications. <i>Medicine (Baltimore).</i> 2016;95:e3978.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/27367996/</p>
<p>Hsieh MH, Lin CY, Wang CY, et al. Impact of concomitant nontuberculous mycobacteria and <i>Pseudomonas aeruginosa</i> isolates in non-cystic fibrosis bronchiectasis. <i>Infect Drug Resist.</i> 2018;11:1137-1143.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/30127630/</p>
<p>Hwang JA, Kim S, Jo KW, Shim TS. Natural history of <i>Mycobacterium avium</i> complex lung disease in untreated patients with stable course. <i>Eur Respir J.</i> 2017;49:1600537.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/28275170/</p>
<p>Izumi K, Morimoto K, Uchimura K, Ato M, Hasegawa N, Mitarai S. Population-based survey of antimycobacterial drug use among patients with non-tuberculosis mycobacterial pulmonary disease. <i>ERJ Open Res.</i> 2020;6:00097-2019.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/32211437/</p>
<p>Kim HO, Lee K, Choi HK, Ha S, Lee SM, Seo GH. Incidence, comorbidities, and treatment patterns of nontuberculous mycobacterial infection in South Korea. <i>Medicine (Baltimore).</i> 2019;98:e17869.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/31702652/</p>

Kim RD, Greenberg DE, Ehrmantraut ME, et al. Pulmonary nontuberculous mycobacterial disease: Prospective study of a distinct preexisting syndrome. <i>Am J Respir Crit Care Med.</i> 2008;178:1066-1074.	https://pubmed.ncbi.nlm.nih.gov/18703788/
Koh WJ, Jeong BH, Jeon K, et al. Clinical significance of the differentiation between <i>Mycobacterium avium</i> and <i>Mycobacterium intracellulare</i> in <i>M avium</i> complex lung disease. <i>Chest.</i> 2012;142:1482-1488.	https://pubmed.ncbi.nlm.nih.gov/22628488/
Kwon BS, Lee JH, Koh Y, et al. The natural history of non-cavitary nodular bronchiectatic <i>Mycobacterium avium</i> complex lung disease. <i>Respir Med.</i> 2019;150:45-50.	https://pubmed.ncbi.nlm.nih.gov/30961950/
Lipman M, Kunst H, Loebinger MR, Milburn HJ, King M. Non tuberculous mycobacteria pulmonary disease: Patients and clinicians working together to improve the evidence base for care [published online ahead of print, 2021 Mar 26]. <i>Int J Infect Dis.</i> 2021;S1201-9712(21)00282-4.	https://pubmed.ncbi.nlm.nih.gov/33781905/
Mazumder SA, Hicks A, Norwood J. <i>Mycobacterium gordonae</i> pulmonary infection in an immunocompetent adult. <i>N Am J Med Sci.</i> 2010;2:205-207.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3354412/
Mediavilla-Gradolph MC, De Toro-Peinado I, Bermúdez-Ruiz MP, et al. Use of MALDI-TOF MS for identification of nontuberculous <i>mycobacterium</i> species isolated from clinical specimens. <i>Biomed Res Int.</i> 2015;2015:854078.	https://downloads.hindawi.com/journals/bmri/2015/854078.pdf
Moon P, Guillaumin E, Chan ED. Non-tuberculous mycobacterial lung disease due to multiple "minor" risk factors: An illustrative case and a review of these "lesser elements". <i>J Thorac Dis.</i> 2020;12:4960-4972.	https://pubmed.ncbi.nlm.nih.gov/33145070/
Moon SM, Jhun BW, Baek SY, et al. Long-term natural history of non-cavitary nodular bronchiectatic nontuberculous mycobacterial pulmonary disease. <i>Respir Med.</i> 2019;151:1-7.	https://pubmed.ncbi.nlm.nih.gov/31047103/
Nishiuchi Y, Iwamoto T, Maruyama F. Infection sources of a common non-tuberculous mycobacterial pathogen, <i>Mycobacterium avium</i> complex. <i>Front Med (Lausanne).</i> 2017;4:27.	https://pubmed.ncbi.nlm.nih.gov/28326308/
Oshitani, Y., Kitada, S., Edahiro, R. et al. Characteristic chest CT findings for progressive cavities in <i>Mycobacterium avium</i> complex pulmonary disease: A retrospective cohort study. <i>Respir Res.</i> 2020;21:10.	https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-020-1273-x
Pennington KM, Vu A, Challener D, et al. Approach to the diagnosis and treatment of non-tuberculous	https://pubmed.ncbi.nlm.nih.gov/34036184/

<p>mycobacterial disease. <i>J Clin Tuberc Other Mycobact Dis.</i> 2021;24:100244.</p>	
<p>Prevots DR, Marras TK. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: A review. <i>Clin Chest Med.</i> 2015;36:13-34.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/25676516/</p>
<p>Prevots DR, Shaw PA, Strickland D, et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. <i>Am J Respir Crit Care Med.</i> 2010;182:970-976.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/20538958/</p>
<p>Ratnatunga CN, Lutzky VP, Kupz A, et al. The rise of non-tuberculosis mycobacterial lung disease. <i>Front Immunol.</i> 2020;11:303.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/32194556/</p>
<p>Swenson C, Lapinel NC, Ali J. Clinical management of respiratory adverse events associated with amikacin liposome inhalation suspension: Results from a patient survey. <i>Open Forum Infect Dis.</i> 2020;7:ofaa079.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/32322600/</p>
<p>To K, Cao R, Yegiazaryan A, Owens J, Venketaraman V. General overview of nontuberculous mycobacteria opportunistic pathogens: <i>Mycobacterium avium</i> and <i>Mycobacterium abscessus</i>. <i>J Clin Med.</i> 2020;9:2541.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/32781595/</p>
<p>van Ingen J, Aliberti S, Andrejak C, et al. Management of drug toxicity in <i>Mycobacterium avium</i> complex pulmonary disease: An expert panel survey. <i>Clin Infect Dis.</i> 2021;73:e256-e259.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/32910814/</p>
<p>Weiss CH, Glassroth J. Pulmonary disease caused by nontuberculous mycobacteria. <i>Expert Rev Respir Med.</i> 2012;6:597-613.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/23234447/</p>
<p>Winthrop KL Yamashita S, Beekmann SE, Polgreen PM; Infectious Diseases Society of America Emerging Infections Network. Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: Case finding through the emerging infections network. <i>Clin Infect Dis.</i> 2008;46:1738-1740.</p>	<p>https://academic.oup.com/cid/article/46/11/1738/376054</p>
<p>Winthrop KL, Chang E, Yamashita S, Iademarco MF, LoBue PA. Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy. <i>Emerg Infect Dis.</i> 2009;15:1556-1561.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/19861045/</p>